Table 2 Demographic and clinical characteristics of the proliferative diabetic retinopathy (PDR) groups at baseline.
From: Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial
Placebo (n = 18) | Levosulpiride (n = 18) | p | |
|---|---|---|---|
Age years (SD) | 57.6 (6.4) | 56.2 (8.6) | 0.58a |
Sex F n (%) | 10 (55.6) | 9 (50) | 0.73b |
BMI (kg/m2) (SD) | 28.2 (5.1) | 28.5 (9.4) | 0.42c |
DM2 years (SD) | 15.8 (5.9) | 16.0 (6.3) | 0.92a |
HbA1c, % (SD) | 7.5 (1.4) | 8.0 (1.9) | 0.42a |
SCr mg/dl (SD) | 1.2 (0.5) | 1.0 (0.4) | 0.27c |
eGFR ml/min) (SD) | 69.9 (24.8) | 83.8 (27.4) | 0.12a |
SPRL ng/ml (SD) | 7.7 (4.0) | 10.3 (5.7) | 0.10c |